https://pharmadevicenews.com/organons-vtama-achieved-up-to-70-easi75-response-in-one-eczema-subgroup-how-broadly-do-the-results-apply/ PharmaDeviceNews en 2026-11-13T08:14:06+00:00 Organon’s VTAMA achieved up to 70% EASI75 response in one eczema subgroup. How broadly do the results apply? ADORING 1, ADORING 2, ADORING 3, American College of Allergy Asthma and Immunology, Dermavant Sciences, Organon, Sun Pharmaceutical Industries, tapinarof, VTAMA https://pharmadevicenews.com/wp-content/uploads/2026/01/severe-atopic-dermatitis-symptoms.webp https://pharmadevicenews.com/kalvistas-oral-hae-drug-is-approved-now-five-studies-are-testing-what-treatment-changes-in-real-life/ PharmaDeviceNews en 2026-11-13T08:11:08+00:00 KalVista’s oral HAE drug is approved. Now five studies are testing what treatment changes in real life American College of Allergy Asthma and Immunology, Chiesi Global Rare Diseases, Chiesi Group, EARLY, EKTERLY, KalVista Pharmaceuticals, KONFIDENT, KONFIDENT-S, sebetralstat https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/volta-labs-cuts-axelios-1-library-prep-hands-on-time-to-one-hour-can-laboratories-scale-faster/ PharmaDeviceNews en 2026-11-13T08:08:17+00:00 Volta Labs cuts AXELIOS 1 library prep hands-on time to one hour. Can laboratories scale faster? Association for Molecular Pathology, AXELIOS 1, Callisto, Genome in a Bottle, Roche, Roche Diagnostics, SBX-D, Volta Labs https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic.webp https://pharmadevicenews.com/mitotech-is-testing-a-different-way-to-burn-fat-could-mt-1101-complement-glp-1-drugs/ PharmaDeviceNews en 2026-11-13T08:05:06+00:00 Mitotech is testing a different way to burn fat. Could MT-1101 complement GLP-1 drugs? Anton Petrov, Mitotech, MT-1101, Natalia Perekhvatova, ObesityWeek, semaglutide, The Obesity Society https://pharmadevicenews.com/wp-content/uploads/2026/09/Oral-metabolic-drug-research-e1790707052160.webp https://pharmadevicenews.com/cambrian-bios-atx-304-raised-resting-metabolic-rate-by-up-to-33-could-obesity-treatment-move-beyond-appetite-suppression/ PharmaDeviceNews en 2026-11-13T08:01:51+00:00 Cambrian Bio’s ATX-304 raised resting metabolic rate by up to 33%. Could obesity treatment move beyond appetite suppression? American Diabetes Association, ATX-304, Cambrian Bio, Cambrian BioPharma, ObesityWeek, REWIRE-1, REWIRE-2, The Obesity Society https://pharmadevicenews.com/wp-content/uploads/2026/04/Khondrion-begins-pivotal-sonlicromanol-study-in-m.3243AG-disease-with-a-sharper-regulatory-strategy-e1776657813549.webp https://pharmadevicenews.com/lineage-buys-a-huntingtons-disease-cell-therapy-with-six-patients-treated-can-hunt1-overcome-the-next-hurdle/ PharmaDeviceNews en 2026-11-13T03:58:39+00:00 Lineage buys a Huntington’s disease cell therapy with six patients treated. Can HUNT1 overcome the next hurdle? Brian Culley, California Institute for Regenerative Medicine, hNSC-01, HUNT1, Leslie Thompson, Lineage Cell Therapeutics, NeuroAirmid Therapeutics, REGEN4HD, University of California Irvine https://pharmadevicenews.com/wp-content/uploads/2026/07/Huntingtons-disease-drug-research-e1783863352980.webp https://pharmadevicenews.com/ardent-health-is-buying-a-480m-revenue-hospital-system-for-47m-whats-behind-the-deal/ PharmaDeviceNews en 2026-11-13T03:55:43+00:00 Ardent Health is buying a $480m revenue hospital system for $47m. What’s behind the deal? Ardent Health, Boone Health, Boone Health Medical Group, Boone Hospital Center, Columbia, Dave Caspers, Missouri https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/diamedica-has-reached-200-stroke-trial-patients-could-its-next-two-readouts-change-dm199s-future/ PharmaDeviceNews en 2026-11-13T03:52:08+00:00 DiaMedica has reached 200 stroke trial patients. Could its next two readouts change DM199’s future? DiaMedica Therapeutics, DM199, Health Canada, ReMEDy2, Tygerberg Hospital, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/what-veradermics-latest-oral-minoxidil-data-reveal-about-long-term-hair-growth/ PharmaDeviceNews en 2026-11-13T03:48:39+00:00 What Veradermics’ latest oral minoxidil data reveal about long-term hair growth Jefferies, Study 302, Study 304, Study 306, United States Food and Drug Administration, VDPHL01, Veradermics https://pharmadevicenews.com/wp-content/uploads/2026/07/VDPHL01-female-hair-loss-data-to-test-Veradermics-extended-release-minoxidil-strategy-e1784095007570.webp https://pharmadevicenews.com/aptar-pharma-just-removed-a-critical-development-barrier-for-complex-nasal-drugs-how-much-could-change/ PharmaDeviceNews en 2026-11-13T03:45:29+00:00 Aptar Pharma gains DEA registration for controlled-substance nasal and inhaled drug development Aptar Pharma, AptarGroup, Boonton, New Jersey, United States Drug Enforcement Administration https://pharmadevicenews.com/wp-content/uploads/2026/05/Aptar-Pharma-advances-FDA-backed-research-into-next-generation-metered-dose-inhalers-e1778298889267.webp https://pharmadevicenews.com/pimjetmi-shrank-tumours-in-56-of-tgct-patients-can-merck-kgaa-break-through-an-increasingly-crowded-rare-tumour-market/ PharmaDeviceNews en 2026-11-12T07:09:51+00:00 Pimjetmi shrank tumours in 56% of TGCT patients. Can Merck KGaA break through an increasingly crowded rare-tumour market? Abbisko Medicine, EMD Serono, MANEUVER, Merck KGaA, pimicotinib, Pimjetmi, Romvimza, Turalio https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/risto-cel-stopped-severe-sickle-cell-crises-long-enough-for-beam-to-plan-a-bla-why-did-the-stock-still-fall/ PharmaDeviceNews en 2026-11-12T04:07:51+00:00 Risto-cel stopped severe sickle cell crises long enough for Beam to plan a BLA. Why did the stock still fall? BEACON, Beam Therapeutics, Casgevy, Genetix Biotherapeutics, LYFGENIA, risto-cel, ristoglogene autogetemcel, United States Food and Drug Administration, Vertex Pharmaceuticals https://pharmadevicenews.com/wp-content/uploads/2026/07/Vertex-wins-broader-CASGEVY-approval-as-pediatric-gene-therapy-enters-a-new-phase-e1782965191835.webp https://pharmadevicenews.com/abbott-just-put-physiologic-pacing-and-defibrillation-on-one-lead-can-ultisynq-change-how-icds-are-implanted/ PharmaDeviceNews en 2026-11-12T04:01:59+00:00 Abbott just put physiologic pacing and defibrillation on one lead. Can UltiSynq change how ICDs are implanted? Abbott Laboratories, ASCEND CSP, UltiSynq, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/two-phase-3-wins-put-comp360-before-the-fda-can-compass-pathways-turn-psilocybin-into-a-mainstream-depression-treatment/ PharmaDeviceNews en 2026-11-12T03:58:18+00:00 Two Phase 3 wins put COMP360 before the FDA. Can Compass Pathways turn psilocybin into a mainstream depression treatment? COMP005, COMP006, COMP360, COMPASS Pathways https://pharmadevicenews.com/wp-content/uploads/2026/05/Evecxia-Therapeutics-positions-EVX-101-as-adjunctive-therapy-for-OCD-and-depression-e1780030000546.webp https://pharmadevicenews.com/genedx-analysed-more-than-300000-patients-and-found-actionable-results-in-62-of-positive-cases-why-did-wgs-crash-17/ PharmaDeviceNews en 2026-11-12T03:53:20+00:00 GeneDx analysed more than 300,000 patients and found actionable results in 62% of positive cases. Why did WGS crash 17%? ExomeDx, GeneDx, GeneDx Infinity, GenomeDx, National Society of Genetic Counselors https://pharmadevicenews.com/wp-content/uploads/2026/05/Inocras-CancerVision-data-point-to-a-harder-question-for-ovarian-cancer-diagnostics-e1779511076970.webp